Get the Stockscreener App
3.67
6.69%
0.23
After Hours:
3.68
0.01
+0.27%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.67, with a volume of 5.17M.
It is up +6.69% in the last 24 hours and down -10.05% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$3.44
Open:
$3.47
24h Volume:
5.17M
Relative Volume:
0.93
Market Cap:
$323.90M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-2.2378
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
+1.10%
1M Performance:
-10.05%
6M Performance:
-42.83%
1Y Performance:
-45.22%
1-Day Range:
$3.4286
$3.70
1-Week Range:
$3.35
$3.70
52-Week Range:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.67 | 303.60M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune (ALT) Stock Rises on FDA's Acceptance of Surrogate Endpoint - GuruFocus
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - PR Newswire
Will Altimmune Inc. price bounce be sustainable2025 Trade Ideas & High Conviction Investment Ideas - Newser
Using Python tools to backtest Altimmune Inc. strategiesPortfolio Risk Summary & Growth Focused Entry Point Reports - Newser
Altimmune Inc. stock volume spike explainedTrend Reversal & Accurate Entry/Exit Alerts - Newser
Top chart patterns to watch in Altimmune Inc.2025 Momentum Check & Weekly Breakout Watchlists - Newser
Contact The Gross Law Firm by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc.(ALT) - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, - GlobeNewswire
Altimmune to Participate in Upcoming Investor Conferences - The Manila Times
Late-Stage Biotech Altimmune Announces Triple Conference Presence: Wells Fargo, HC Wainwright, Morgan Stanley - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming DeadlinesALT - WV News
Levi & Korsinsky Moves to SueWallSt for Altimmune, Inc. Investors That Lost Money - Stockhouse
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Is Altimmune Inc. still worth holding after the dip2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
Real time breakdown of Altimmune Inc. stock performanceJuly 2025 Recap & Free Technical Pattern Based Buy Signals - Newser
Class Action Filed Against Altimmune, Inc. (ALT)October 6, 2025 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire
Altimmune, Inc. Sued for Securities Law Violations - GlobeNewswire
Faruqi & Faruqi investigates potential claims against Altimmune, Inc. - AInvest
ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc. - PR Newswire
Will Altimmune Inc. continue its uptrend2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Altimmune wins FDA fast track status for alcohol use disorder therapy - MSN
Will Altimmune Inc. stock recover after recent dropQuarterly Market Summary & Precise Trade Entry Recommendations - Newser
Altimmune Inc (ALT) Stock: A Comprehensive 52-Week Review - investchronicle.com
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Altimmune (ALT) Gains FDA Fast Track for Alcohol Use Disorder Treatment - GuruFocus
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - MarketScreener
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) | ALT Stock News - GuruFocus
Altimmune's Pemvidutide Receives FDA Fast Track Designation for Alcohol Use Disorder Treatment - Quiver Quantitative
Trend analysis for Altimmune Inc. this weekMarket Activity Recap & Scalable Portfolio Growth Ideas - Newser
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Before October 6, 2025Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel - GlobeNewswire
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights - PR Newswire
ALT LAWSUIT ALERT: The Gross Law Firm Notifies Altimmune, - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. LawsuitALT - PR Newswire
Altimmune Inc. stock trend outlook and recovery pathWeekly Trend Report & Low Drawdown Investment Strategies - Newser
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):